The aim of the study was to analyze and detect prognostic factors in surgically treated patients with synchronous single-organ metastasis from NSCLC.\n\nMethods: This is a retrospective single-center study including 29 patients with synchronous single-organ metastatic NSCLC who underwent lung resection and local treatment of the metastasis between 2002 and 2008. Overall survival was estimated from the date of lung surgery until last follow-up. The impact on survival of nine variables (age, pT, pN, site of metastasis, presence of solitary metastasis. R-resection status, presence of neoadjuvant or adjuvant

treatment, tumor histology) were further assessed.\n\nResults: Twenty-nine patients (20 males, 69%) with a median age of 62 (from 44 to 77) were included. Site of metastatic disease was the brain in 19, the lung in 8 and the adrenal glands in 2 patients. Histology was adenocarcinoma in 21, large-cell carcinoma CT99021 chemical structure in 3, squamous-cell carcinoma in 2 and other in 3 patients. Type of lung resection performed for primary tumors

were pneumonectomy in 3, bilobar resection in 3, lobar resection in 17 and sublobar resection in 6 patients. Survival at 1 and 5 years for the overall population reached 65% and 36%, respectively. Median survival was 20.5 months. Univariate regression model,analysis identified pathologic T stage as a predictor of survival. Patients with pT1-2 behaved statistically significantly

better (p = 0.007) compared to patients with pT3-4 tumors. No impact on survival for Selleckchem MRT67307 the other 8 variables has been shown.\n\nConclusions: LY2090314 The 5-year survival rate of 36% confirms that multimodality treatment including surgical lung resection should be considered in the therapy of single-site metatastatic NSCLC for selected patients. Pathologic T stage appeared to have significant impact on predicting patient survival. (C) 2012 Elsevier Ireland Ltd. All rights reserved.”
“Background: Acyclovir is acyclic guanosine derivative. Benzylpenicillin (PCG) is a beta-lactam antibiotic. The purpose of this study was to investigate the pharmacokinetic drug-drug interaction (DDI) between PCG and acyclovir.\n\nMethod: When acyclovir and PCG were co-administered, plasma concentration of acyclovir, urinary excretion of acyclovir in vivo, uptake of acyclovir in kidney slices and uptake of acyclovir in human (h) OAT1/hOAT3-HEK293 cells were determined to examine the effect of PCG on urinary excretion of acyclovir.\n\nResults: The plasma concentration of acyclovir was increased markedly and accumulative renal excretion and renal clearance of acyclovir were decreased significantly after intravenous administration of acyclovir in combination with PCG. PCG could decrease the uptake of acyclovir in kidney slices and in hOAT1-/hOAT3-human embryonic kidney (HEK293) cells.